We are live on ! Find out more
CPIX icon

Cumberland Pharmaceuticals

31 hedge funds and large institutions have $12.3M invested in Cumberland Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 10 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,533% more call options, than puts

Call options by funds: $245K | Put options by funds: $15K

6.03% less ownership

Funds ownership: 30.64%24.61% (-6%)

6% less funds holding

Funds holding: 3331 (-2)

10% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 10

25% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 8

32% less capital invested

Capital invested by funds: $18.1M → $12.3M (-$5.82M)

Holders
31
Holders Change
-2
Holders Change %
-6.06%
% of All Funds
0.41%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
6
Increased
9
Reduced
10
Closed
8
Calls
$245K
Puts
$15K
Net Calls
+$230K
Net Calls Change
-$742K
Name Holding Trade Value Shares
Change
Change in
Stake
Millennium Management
1
Millennium Management
New York
$2.6M -$161K -33,921 -4%
IC
2
Ikarian Capital
Texas
$2M -$682K -144,068 -19%
Renaissance Technologies
3
Renaissance Technologies
New York
$1.66M -$39.8K -8,400 -2%
Vanguard Group
4
Vanguard Group
Pennsylvania
$1.38M -$22.7K -4,783 -1%
Dimensional Fund Advisors
5
Dimensional Fund Advisors
Texas
$847K +$3.32K +700 +0.3%
JGC
6
J. Goldman & Co
New York
$739K -$98.4K -20,774 -9%
BCM
7
Bridgeway Capital Management
Texas
$631K +$19.9K +4,200 +2%
BFM
8
Boothbay Fund Management
New York
$604K -$206K -43,569 -19%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$336K +$5.43K +1,146 +1%
Citadel Advisors
10
Citadel Advisors
Florida
$249K +$230K +48,592 +188%
Bank of New York Mellon
11
Bank of New York Mellon
New York
$243K
BlackRock
12
BlackRock
New York
$171K +$87.7K +18,510 +57%
Acadian Asset Management
13
Acadian Asset Management
Massachusetts
$148K -$23K -4,849 -10%
State Street
14
State Street
Massachusetts
$113K
HBCM
15
Heron Bay Capital Management
Michigan
$111K +$158K +33,251 New
Two Sigma Investments
16
Two Sigma Investments
New York
$108K +$45K +9,510 +42%
Northern Trust
17
Northern Trust
Illinois
$65.7K
CAM
18
Cresset Asset Management
Illinois
$61.9K -$7.11K -1,500 -8%
Simplex Trading
19
Simplex Trading
Illinois
$47K -$23.1K -4,882 -26%
Morgan Stanley
20
Morgan Stanley
New York
$41.5K +$46.1K +9,738 +366%
Susquehanna International Group
21
Susquehanna International Group
Pennsylvania
$38.6K -$82.5K -17,412 -60%
P
22
&Partners
Tennessee
$36.9K
XT
23
XTX Topco
Cayman Islands
$34.4K +$48.7K +10,280 New
UBS Group
24
UBS Group
Switzerland
$29.5K +$16.5K +3,481 +65%
Group One Trading
25
Group One Trading
Illinois
$27.5K +$38.9K +8,222 New

CPIX Hedge Fund Activity: Q2 2025 in Review

31 of the 7,603 institutional investors tracked by Wall St. Rank reported a position in Cumberland Pharmaceuticals (CPIX) for Q2 2025, worth a combined $12.3M — down 32% from $18.1M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of CPIX and 6 opened new positions — a net loss of 2 holders — while 10 trimmed existing stakes and 9 added.

The largest buyer was Citadel Advisors, adding an estimated $230K. The largest seller was Berkshire Asset Management, exiting entirely with an estimated $692K sold.

  • 31 institutional investors held Cumberland Pharmaceuticals (CPIX) as of Q2 2025, down from 33 in Q1 2025.
  • Funds reported $12.3M of Cumberland Pharmaceuticals stock for Q2 2025, down 32% quarter-over-quarter.
  • 6 funds opened new Cumberland Pharmaceuticals positions in Q2 2025 and 8 closed out, a net change of -2 holders.
  • The largest Cumberland Pharmaceuticals buyer in Q2 2025 was Citadel Advisors, an estimated $230K added.
  • The largest Cumberland Pharmaceuticals seller in Q2 2025 was Berkshire Asset Management, an estimated $692K sold.

Based on aggregated 13F filings for Q2 2025.